P4HB and glioblastoma: In 2020, Shergalis et al. published some aminobenzophenol-basedscaffolds as PDI inhibitors to treat GBM.72 First, the authors screened approximately 1000 compounds from theNational Cancer Institute and found 94 and 95 as potent lead compounds (PDI reductase assay), with IC50 = 300 and 90 nM, respectively.